8月29日 - ** 生物技术公司NeoGenomics NEO.O股价盘前上涨10.9%至8美元
** 在对NateraNTRA.O的专利侵权诉讼中，该公司赢得了 (link) 简易判决。
** 该公司表示，法院将驳回 Natera 对 NeoGenomics 提出的诉讼请求。
** 法院命令意味着NEO仍可自由销售其名为RaDaR ST检测法的早期乳腺癌筛查产品。
** 该诊断设备是一种测序检验，用于检测乳腺癌的最小残留病(MRD) 和复发。
** 截至上次收盘，NEO年累计下跌56.3%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.